Inovio Pharmaceuticals Files 8-K with Financial Updates

Ticker: INO · Form: 8-K · Filed: May 13, 2024 · CIK: 1055726

Inovio Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyInovio Pharmaceuticals, INC. (INO)
Form Type8-K
Filed DateMay 13, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financial-results, sec-filing

Related Tickers: INO

TL;DR

INOVIO just dropped its 8-K with financial statements - check it out!

AI Summary

On May 13, 2024, Inovio Pharmaceuticals, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits, providing an update on the company's performance and condition. The report is filed under the Securities Exchange Act of 1934.

Why It Matters

This 8-K filing provides investors with crucial, up-to-date financial information and operational details for Inovio Pharmaceuticals, Inc., enabling informed investment decisions.

Risk Assessment

Risk Level: medium — 8-K filings, especially those detailing financial results, can significantly impact stock prices based on the disclosed information.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Inovio Pharmaceuticals, Inc.'s results of operations and financial condition, as well as to provide financial statements and exhibits.

When was this report filed?

This report was filed on May 13, 2024.

What is the company's state of incorporation?

The company, Inovio Pharmaceuticals, Inc., is incorporated in Delaware.

What is the Commission File Number for Inovio Pharmaceuticals, Inc.?

The Commission File Number for Inovio Pharmaceuticals, Inc. is 001-14888.

What is the business address of Inovio Pharmaceuticals, Inc.?

The business address of Inovio Pharmaceuticals, Inc. is 660 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462.

Filing Stats: 536 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-05-13 16:10:59

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number 99.1 Press Release, dated May 13, 2024 104 Cover Page Interactive Data File (formatted as inline XBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INOVIO PHARMACEUTICALS, INC. Date: May 13, 2024 By: /s/ Peter Kies Peter Kies Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing